Skip to main content
. 2021 Nov 19;12:794638. doi: 10.3389/fimmu.2021.794638

Figure 4.

Figure 4

Leronlimab treatment of an SIVmac239-infected macaque. A cynomolgus macaque (n=1; 36484) was chronically infected with SIVmac239 prior to receiving weekly 50 mg/kg SC Leronlimab. (A) Longitudinal Leronlimab concentration in plasma. (B) Longitudinal CCR5 RO by Leronlimab on peripheral CD4+CCR5+ T cells. (C) Longitudinal peripheral blood CCR5+CD4+ T cell frequency. (D) Longitudinal SIV RNA copies per mL plasma. Vertical dashed lines represent each SC Leronlimab injection.